Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) Q4 2025 earnings summary

Executive summary

• Operating revenue reached RMB77.66 billion in 2025, up 3.55% year-over-year; net profit attributable to shareholders was RMB2.98 billion, up 5.21% year-over-year.

• The company maintained its leading position in modernized traditional Chinese medicine, chemical pharmaceuticals, natural beverages, and pharmaceutical commerce.

• Major initiatives included strengthening the TCM and API businesses, expanding international presence, and advancing digital transformation.

• R&D focused on oncology, chronic diseases, respiratory, immune, and men's health, with over 160 projects in the pipeline.

• No significant events occurred that would impact ongoing operations; no risk of delisting.

Financial highlights

• Operating revenue: RMB77.66 billion (+3.55% YoY); net profit attributable to shareholders: RMB2.98 billion (+5.21% YoY).

• Total assets: RMB84.51 billion (+3.46% YoY); net assets attributable to shareholders: RMB37.79 billion (+5.25% YoY).

• Basic EPS: RMB1.835 (+5.21% YoY); weighted average ROE: 8.09%.

• Net cash flow from operating activities: -RMB232 million (down from +RMB3.44 billion in 2024).

• Proposed cash dividend: RMB0.45 per share, totaling RMB731.6 million.

Outlook and guidance

• 2026 strategy focuses on quality and efficiency improvement, innovation, internationalization, and digital transformation.

• Plans to increase R&D investment, accelerate product launches, and expand global market presence.

• Capital expenditure for 2026 expected at RMB2.15 billion, mainly for production base construction and equipment upgrades.